We have shown that prostate cancer occurring in men with germline BRCA1 and BRCA2 mutations is more aggressive.
In an attempt to identify an associated immunohistochemical phenotype, we have studied TP53 immunostaining
in prostate cancers in mutation carriers versus prostate cancers occurring in a control group of men.
There was a significantly higher expression of TP53 protein in prostate cancer with a higher Gleason score (p< 0.001).
Twenty four per cent of prostate cancer occurring in BRCA1/2 mutation carriers and 19% of those from controls stained
positively for the TP53 protein; this difference was not significant.
Over expression of TP53 cannot distinguish prostate cancer on a background of BRCA1/2 mutation, but it is associated
with prostate cancer malignant tissue per se, in particular aggressive disease.